Skip to main content
CBUS logo

CBUS

Cibus, Inc.
$2.02 +0.12 (+6.32%) At close · Jul 10
Market Cap
$154.19M
Shares
76,331,634

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.02 Open$1.92 Day$1.84–2.20 52W$1.09–4.19 Avg vol 30d355K Short int4.6M · 6.1% float · 16.2d Short vol43% Last earningsMay 14, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 14
Up next
Next earnings call
Aug 10, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 14, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +12%
      above
      Price vs 50-day avg +43%
      above
      RSI (14) 79
      overbought
      MACD trend Positive
      52-week position 30%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +68%
      trailing
      6-month return +9%
      trailing
      YTD return +16%
      this year
      Relative strength 0%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      1 of 68 funds reported for Jun 30 · net +30.0K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.06% of float · ▼ -5.5% MoM · 16.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      68 holders — mid 3-yr range
      Squeeze score 90
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth −15%
      Y/Y
      Gross margin 4%
      expanding
      EPS growth +74%
      Y/Y
      Free cash flow $-51.2M
      Balance sheet $9.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 106%
      annualized · 1-yr
      Max drawdown −70%
      past year
      ATR 8.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 14, 2026
      Annual net cash usage · 2026 Initiated at least $30M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +12% Bullish
      Price vs 50-day avg
      +43% Bullish
      RSI (14)
      79 Bearish
      MACD trend
      Positive Bullish
      52-week position
      30% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      1 of 68 funds reported for Jun 30 · net +30.0K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.06% of float · ▼ -5.5% MoM · 16.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      68 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $1 Now $2 · 30% 52-wk high $4
      vs 200-day avg +12% vs 50-day avg +43%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CBUS
      Cibus, Inc.
      this stock
      $154.19M +16.1% -14.6% 6.1%
      ONC
      BeOne Medicines Ltd.
      $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $69.67B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      $54.85B +4.4% 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      69
      % held
      29.1%
      Reported
      1 of 68
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      21
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      4.6M
      Days to cover
      16.2d
      Change
      -272.0K sh
      View
      Short Volume
      Short vol %
      43%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      22
      Value
      $27
      As of
      Jun 10, 2026
      View
      Off-Exchange
      Off-exchange %
      51.0%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $3.6M
      Net income (FY)
      $-127.1M
      EPS diluted
      $-2.78
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $343.1K
      Shares
      71.8K
      Filed
      Nov 18, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 14, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CBUS +45.3% +68.3% +8.6% +47.5% +16.1%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY +44.0% +64.3% -0.5% +46.4% +5.4%
      Key facts CIK 1705843 CUSIP 17166A101 13F (30d) 1 filings 1 filers Visit website Investor relations